RenovoRx
Open
$0.86
Prev. Close
$0.86
High
$0.86
Low
$0.86
Market Snapshot
$30.46M
-2.7
-0.48
$240K
10
RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a therapy platform to deliver chemotherapy. The company is headquartered in Mountain View, California and currently employs 10 full-time employees. The company went IPO on 2021-08-17. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.
emptyResult
RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a therapy platform to deliver chemotherapy. The company is headquartered in Mountain View, California and currently employs 10 full-time employees. The company went IPO on 2021-08-17. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.
Recently from Cashu
RenovoRx Raises $12.1 Million to Advance Oncology Innovations and Clinical Development
RenovoRx Secures $12.1 Million in Public Offering to Propel Oncology Innovations RenovoRx, Inc., a pioneering life sciences firm focused on oncology therapies, successfully concludes a $12.1 million p…
RenovoRx Secures $12.1M Funding to Advance Innovative Oncology Therapies and Clinical Trials
RenovoRx Secures Funding to Propel Innovative Oncology Therapies RenovoRx, Inc. successfully completes a $12.1 million public offering of common stock, marking a significant step in its pursuit of gro…
RenovoRx Launches $12.1M Offering to Advance Targeted Oncology Solutions and TIGeR-PaC Study
RenovoRx Advances Oncology Solutions with New Funding Initiative RenovoRx, Inc., a life sciences company specializing in targeted oncology therapies, announces the launch of an underwritten public off…
RenovoRx Launches Public Offering to Advance Oncology and Support Innovative Cancer Treatments
RenovoRx Advances Oncology Therapy with New Offering RenovoRx, Inc., a life sciences company based in Mountain View, California, is making significant strides in the oncology sector with the announcem…